血浆pTau217与NfL联合MRI鉴别进行性核上性麻痹与帕金森病
本研究在台湾多中心队列中测量血浆pTau217、pTau181、pTau231、NfL和GFAP,探索性队列含67例PSP、64例PD等共195人,验证队列含80例PSP。结果显示血浆pTau217联合NfL及中脑-脑桥比值的AUC为0.946,验证队列AUC为0.825,可无创区分PSP与PD。
要点
- PSP和CBS患者血浆pTau217、pTau181、pTau231及NfL水平高于其他组。
- pTau217联合NfL与中脑-脑桥比值鉴别PSP与PD的AUC达0.946。
- 该联合方案在独立验证队列中AUC为0.825,具有临床可行性。
核心结论
- 血浆pTau217与NfL联合脑MRI中脑-脑桥比值可无创、临床可行地区分PSP与PD。
研究设计与样本
- 多中心队列研究,探索性队列195人(46例对照、64例认知正常PD、18例CBS、67例PSP),验证队列80例临床诊断PSP。
主要发现
- PSP和CBS患者血浆pTau217、pTau181、pTau231及NfL水平高于其他组(均p < 0.05)。
- PSP探索性队列中,pTau217(r = -0.270, p = 0.031)、NfL(r = -0.363, p = 0.003)和GFAP(r = -0.264, p = 0.035)与认知表现负相关,仅NfL与PSP评定量表评分相关(r = 0.303, p = 0.023)。
- CBS中血浆pTau217与皮层tau负荷正相关,PSP中与18F-florzolotau PET丘脑底核tau摄取负相关。
- pTau217联合NfL及中脑-脑桥比值鉴别PSP与PD的AUC为0.946(p < 0.0001),与18F-florzolotau PET的AUC 0.870(p = 0.001)相当,验证队列AUC为0.825(p < 0.0001)。
临床怎么用
- 对于早期帕金森综合征患者,可考虑检测血浆pTau217和NfL并结合脑MRI中脑-脑桥比值辅助鉴别PSP与PD。
局限性
- 验证队列的PSP为临床诊断,未行18F-florzolotau PET确认tau病理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Progressive supranuclear palsy (PSP) is a 4-repeat tauopathy neurodegenerative disorder that presents with parkinsonism features and is often indistinguishable from Parkinson disease (PD) in the early stages. The potential of plasma levels of phosphorylated tau (pTau) to differentiate PSP from PD remains unclear. The aim of this study was to identify noninvasive, cost-effective alternatives to tau PET imaging for differentiating PSP from PD. METHODS: We measured plasma biomarkers, including pTau species (pTau217, pTau181, and pTau231), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP), in 2 cohorts recruited from multiple centers across Taiwan. The exploratory cohort included patients with PSP and corticobasal degeneration (CBS) who underwent 18F-florzolotau PET to confirm underlying tau pathology. All participants with PSP and CBS in this cohort were confirmed negative for amyloid pathology based on either amyloid PET imaging or the plasma Aβ42/Aβ40 ratio. An independent validation cohort, consisting of clinically diagnosed PSP patients without 18F-florzolotau PET imaging, was also recruited. RESULTS: A total of 275 participants were included in this study: 195 participants in the exploratory cohort (46 controls, 64 patients with PD and normal cognition, 18 patients with CBS, and 67 patients with PSP) and 80 patients with PSP in the validation cohort. Patients with PSP and CBS had higher levels of pTau217, pTau181, pTau231, and NfL compared with the other groups (all p < 0.05). In the PSP exploratory cohort, plasma levels of pTau217 (r = -0.270, p = 0.031), NfL (r = -0.363, p = 0.003), and GFAP (r = -0.264, p = 0.035) negatively correlated with cognitive performance, while only NfL levels were associated with PSP Rating Scale scores (r = 0.303, p = 0.023). Plasma pTau217 levels positively correlated with cortical tau burden in CBS but negatively correlated with tau tracer uptake in the subthalamic nucleus on 18F-florzolotau PET in PSP. The combination of pTau217 and NfL with the midbrain-to-pons ratio on brain MRI showed satisfactory performance in differentiating PSP from PD (area under the curve [AUC] 0.946, p < 0.0001), which was comparable to 18F-florzolotau PET (AUC 0.870, p = 0.001) and confirmed in the validation cohort (AUC 0.825, p < 0.0001). DISCUSSION: The combination of plasma pTau217 and NfL with brain MRI represents a noninvasive and clinically feasible strategy for distinguishing PSP from PD.
引用
- Li CH, Fan SP, Chen PS, et al. Plasma pTau217 and Neurofilament Light Chain as Differentiative Markers for Progressive Supranuclear Palsy From Parkinson Disease. Neurology. 2025. PMID: 41385755. doi:10.1212/WNL.0000000000214406
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。